(Reuters) -AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab – the existing standard of care – improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza, jointly developed with U.S.-based Merck & Co, was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations.
Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
(Reporting by Yadarisa Shabong and Aby Jose Koilparambil in Bengaluru; Editing by Savio D’Souza and Janane Venkatraman)
